Ibio Inc Stock Research

Market Summary

USD2.03+0.19

Market Closed

10.33%

IBIO Stock Price

IBIO RSI Chart

IBIO Valuation

Market Cap

25.1M

Price/Earnings (Trailing)

-0.31

Price/Sales (Trailing)

3.21

Price/Free Cashflow

-0.52

IBIO Price/Sales (Trailing)

IBIO Profitability

Return on Equity

-431%

Return on Assets

-156.62%

Free Cashflow Yield

-193.36%

IBIO Fundamentals

IBIO Revenue

Revenue Y/Y

-87.58%

Revenue Q/Q

-96.86%

IBIO Earnings

Earnings (TTM)

-81.1M

Earnings Y/Y

-181.48%

Earnings Q/Q

-85.07%

Price Action

52 Week Range

0.3616.51

(Low)(High)

Last 7 days

-6.1%

Last 30 days

94.0%

Last 90 days

306.9%

Trailing 12 Months

-77.1%

IBIO Financial Health

Current Ratio

1.38

IBIO Investor Care

Shares Dilution (1Y)

41.92%

Diluted EPS (TTM)

-9

Peers (Alternatives to Ibio)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	125.3B	26.3B	-2.75%	3.76%	19.12	4.76	1.32%	11.18%
GILD	99.6B	27.3B	-8.96%	41.01%	21.68	3.65	-0.09%	-26.23%
MRNA	58.4B	19.3B	-12.76%	1.00%	6.99	3.03	4.29%	-31.47%
BIIB	38.3B	10.2B	-9.67%	32.94%	12.57	3.76	-7.36%	95.80%
MID-CAP
NBIX	9.1B	1.5B	-9.09%	3.35%	58.87	6.11	31.34%	72.43%
DNLI	3.2B	108.5M	-21.10%	-19.55%	-9.78	29.38	122.90%	-12.19%
BEAM	2.5B	60.9M	-18.47%	-36.46%	-8.76	41.55	17.51%	22.00%
BBIO	2.1B	107.9M	22.95%	67.45%	-4.29	19.27	54.84%	17.36%
SMALL-CAP
RCUS	1.2B	112.0M	-14.86%	-46.41%	-4.63	11.04	-70.76%	-603.77%
REPL	1.1B	7.0M	-22.18%	24.65%	-7.11	158.97	131.81%	-45.39%
FATE	541.9M	96.3M	-12.99%	-82.24%	-1.92	5.63	72.44%	-32.79%
NVAX	513.7M	2.0B	-39.67%	-92.01%	-0.78	0.26	72.89%	62.27%
SGMO	355.3M	111.3M	-30.55%	-58.78%	-1.85	3.19	0.54%	-7.86%
VXRT	101.4M	159.0K	-16.47%	-82.96%	-0.97	637.62	-86.46%	-64.56%
IBIO	25.1M	-	94.03%	-77.12%	-0.31	3.21	0.51%	-185.61%

Financials for Ibio

* denotes actual numbers (not divided by Thousands)
Income Statement (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-100.0%		2,383	2,686	1,508	2,045
Gross Profit	-10.6%	2,167	2,425	802	1,241	-
Operating Expenses	-5.1%	49,228	51,857	36,360	29,758	-
S&GA Expenses	-6.2%	32,014	34,128	24,719	21,506	-
R&D Expenses	-2.9%	17,214	17,729	11,641	8,252	-
Interest Expenses	-50.9%	693	1,412	1,473	1,835	-
Net Income	-61.3%	-81,127	-50,303	-33,134	-28,405	-
Net Income Margin	-549.8%	-21.11*	-3.25*	-	-	-
Free Cahsflow	-8.3%	-48,548	-44,810	-39,617	-	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-38.7%	52.00	85.00	99.00	115	126
Current Assets	-39.8%	38.00	64.00	45.00	60.00	67.00
Cash Equivalents	-62.6%	4.00	10.00	23.00	34.00	45.00
Inventory	18.8%	4.00	3.00	2.00	-	-
Net PPE	22.5%	4.00	3.00	1.00	35.00	33.00
Liabilities	-8.9%	33.00	36.00	36.00	36.00	36.00
Current Liabilities	-13.7%	28.00	32.00	30.00	8.00	8.00
Shareholder's Equity	-61.1%	19.00	48.00	63.00	79.00	91.00
Retained Earnings	-13.9%	-275	-242	-223	-206	-194
Additional Paid-In Capital	1.4%	295	291	288	286	285
Shares Outstanding	37.3%	12.00	9.00	9.00	9.00	9.00
Minority Interest	NaN%	-	-	-	-	-

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	7.2%	-39,041	-42,092	-37,480	-33,203	-34,608
Share Based Compensation	0.5%	4,802	4,778	4,377	3,794	2,894
Cashflow From Investing	-554.9%	-232	51.00	-5,127	-8,512	-13,043
Cashflow From Financing	60.7%	-1,923	-4,896	-6,125	-3,203	1,545

Risks for IBIO

What is the probability of a big loss on IBIO?

100%

Probability that Ibio stock will be more than 20% underwater in next one year

100%

Probability that Ibio stock will be more than 30% underwater in next one year.

93.8%

Probability that Ibio stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IBIO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Ibio was unfortunately bought at previous high price.

Drawdowns

Returns for IBIO

Cumulative Returns on IBIO

-35.8%

10-Year Cumulative Returns

-47.0%

7-Year Cumulative Returns

-51.0%

5-Year Cumulative Returns

-64.2%

3-Year Cumulative Returns

What are the long-term rolling returns for IBIO?

FIve years rolling returns for Ibio.

Annualized Returns

Which funds bought or sold IBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-02-24	SRS Capital Advisors, Inc.	new	-	16.00	16.00	-%
2023-02-24	NATIXIS	sold off	-100	-33,000	-	-%
2023-02-16	HARBOUR INVESTMENTS, INC.	new	-	356	356	-%
2023-02-15	Steward Partners Investment Advisory, LLC	new	-	28.00	28.00	-%
2023-02-15	Virtu Financial LLC	new	-	21,000	21,000	-%
2023-02-15	UNITED CAPITAL FINANCIAL ADVISERS, LLC	sold off	-100	-2,000	-	-%
2023-02-15	JANE STREET GROUP, LLC	sold off	-100	-5,000	-	-%
2023-02-15	Steward Partners Investment Advisory, LLC	sold off	-100	-	-	-%
2023-02-14	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	59,926	59,926	-%
2023-02-14	Bank of New York Mellon Corp	sold off	-100	-22,000	-	-%

Latest Funds Activity

Are funds buying IBIO calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own IBIO

No. of Funds

Ibio News

Schedule 13G FIlings of Ibio

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	5.28%	475,593	SC 13G
Jul 08, 2022	blackrock inc.	1.8%	3,960,718	SC 13G
Feb 03, 2022	blackrock inc.	7.1%	15,476,683	SC 13G/A
Feb 02, 2021	blackrock inc.	5.5%	11,575,051	SC 13G
Aug 13, 2020	eastern capital ltd	0.6%	1e+06	SC 13D/A
Aug 11, 2020	eastern capital ltd	5.8%	8,629,693	SC 13D/A
Aug 07, 2020	eastern capital ltd	22.3%	33,114,597	SC 13D/A
Aug 06, 2020	eastern capital ltd	22.3%	33,114,597	SC 13D/A
Mar 31, 2020	eastern capital ltd	28.7%	37,382,734	SC 13D/A
Mar 05, 2020	eastern capital ltd	35.6%	37,382,734	SC 13D/A

IBIO Fair Value

Ibio fair value in different scenarios

The table shows the Fair Value estimates for Ibio for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	0.31 -84.73%	0.32 -84.24%	0.38 -81.28%	0.47 -76.85%	0.59 -70.94%
Current Inflation	0.30 -85.22%	0.32 -84.24%	0.37 -81.77%	0.45 -77.83%	0.55 -72.91%
Very High Inflation	0.30 -85.22%	0.32 -84.24%	0.36 -82.27%	0.42 -79.31%	0.51 -74.88%

Historical Ibio Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Ibio

View All Filings

Date Filed	Form Type	Document
Mar 13, 2023	8-K	Current Report
Feb 23, 2023	4	Insider Trading
Feb 22, 2023	424B3	Prospectus Filed
Feb 21, 2023	8-K	Current Report
Feb 16, 2023	8-K	Current Report
Feb 14, 2023	10-Q	Quarterly Report
Feb 14, 2023	3	Insider Trading
Feb 09, 2023	SC 13G	Major Ownership Report
Jan 25, 2023	8-K	Current Report
Jan 24, 2023	4	Insider Trading

Latest Insider Trading transactions for IBIO

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-02-21	Brenner Martin	sold	-7,037	1.77	-3,976	see remarks
2023-01-20	Brenner Martin	acquired	-	-	130,000	interim ceo and cso
2022-11-11	Lutz Robert Matthew	acquired	-	-	100,057	see remarks
2022-11-11	Brenner Martin	acquired	-	-	95,348	chief scientific officer
2022-03-10	Lutz Robert Matthew	sold	-8,510	0.3456	-24,625	see remarks
2021-03-04	Lutz Robert Matthew	acquired	-	-	232,000	see remarks
2020-12-01	Maddux Randy Joe	acquired	-	-	309,000	chief operating officer
2020-08-11	Eastern Capital LTD	sold	-46,330,400	2.9204	-15,864,400	-
2020-08-10	Eastern Capital LTD	sold	-28,429,600	3.9133	-7,264,860	-
2020-08-07	Eastern Capital LTD	sold	-5,185,580	3.8253	-1,355,600	-

About Ibio

Thomas F. Isett

www.ibioinc.com

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

IBIO Income Statement

2022-12-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Condensed Consolidated Statements of Operations and Comprehensive Loss
Revenues	$ 0	$ 0		$ 84
Operating expenses:
Research and development	2,779	1,859	$ 5,327	2,993
General and administrative	7,794	5,372	12,882	9,547
Total operating expenses	10,573	7,231	18,209	12,540
Operating loss	(10,573)	(7,231)	(18,209)	(12,456)
Other income (expense):
Interest expense	(31)	0	(31)
Interest income	41	35	140	71
Royalty income	0	5		5
Total other income (expense)	10	40	109	76
Consolidated net loss from continuing operations	(10,563)	(7,191)	(18,100)	(12,380)
Net loss attributable to noncontrolling interest	0	0		1
Net loss attributable to iBio, Inc. from continuing operations	(10,563)	(7,191)	(18,100)	(12,379)
Preferred stock dividends - iBio CDMO Tracking Stock	0	(22)	0	(88)
Net loss available to iBio, Inc. stockholders from continuing operations	(10,563)	(7,213)	(18,100)	(12,467)
Loss from discontinued operations	(22,990)	(4,729)	(33,583)	(8,480)
Net loss available to iBio, Inc. stockholders	(33,553)	(11,942)	(51,683)	(20,947)
Comprehensive loss:
Consolidated net loss	(33,553)	(11,920)	(51,683)	(20,860)
Other comprehensive loss - unrealized gain ( loss) on debt securities	56	(27)	46	(28)
Comprehensive loss	$ (33,497)	$ (11,947)	$ (51,637)	$ (20,888)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations	$ (1.08)	$ (0.83)	$ (1.94)	$ (1.43)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations	(1.08)	(0.83)	(1.94)	(1.43)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations	(2.34)	(0.54)	(3.60)	(0.97)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations	(2.34)	(0.54)	(3.60)	(0.97)
Loss per common share attributable to iBio, Inc. stockholders - basic - total	(3.42)	(1.37)	(5.54)	(2.40)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total	$ (3.42)	$ (1.37)	$ (5.54)	$ (2.40)
Weighted-average common shares outstanding - basic	9,807	8,715	9,324	8,715
Weighted-average common shares outstanding - diluted	9,807	8,715	9,324	8,715

IBIO Balance Sheet

2022-12-31

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Jun. 30, 2022
Current assets:
Cash and cash equivalents	$ 3,696,000	$ 22,676,000
Investments in debt securities	5,929,000	10,845,000
Accounts receivable - trade	970,000	1,000,000
Settlement receivable - current portion	5,100,000	5,100,000
Convertible promissory note receivable and accrued interest	1,669,000
Prepaid expenses and other current assets	414,000	1,549,000
Current assets held for sale	20,457,000	3,900,000
Total Current Assets	38,235,000	45,070,000
Restricted cash	253,000	5,996,000
Convertible promissory note receivable and accrued interest		1,631,000
Finance lease right-of-use assets, net of accumulated amortization	746,000
Operating lease right-of-use asset	2,873,000	3,068,000
Fixed assets, net of accumulated depreciation	4,245,000	1,373,000
Intangible assets, net of accumulated amortization	5,398,000	4,851,000
Security deposits	50,000	29,000
Prepaid expenses - noncurrent		74,000
Noncurrent assets held for sale		37,314,000
Total Assets	51,800,000	99,406,000
Current liabilities:
Accounts payable	4,002,000	4,264,000
Accrued expenses	5,001,000	3,764,000
Finance lease obligations - current portion	259,000
Operating lease obligation - current portion	315,000	91,000
Equipment financing payable - current portion	152,000
Term note payable - net of deferred financing costs	16,011,000	22,161,000
Contract liabilities	88,000	100,000
Current liabilities related to assets held for sale	1,947,000	56,000
Total Current Liabilities	27,775,000	30,436,000
Finance lease obligations - net of current portion	490,000
Operating lease obligation - net of current portion	3,324,000	3,514,000
Equipment financing payable - net of current portion	323,000
Accrued expenses - noncurrent	1,065,000
Noncurrent liabilities related to assets held for sale		1,971,000
Total Liabilities	32,977,000	35,921,000
iBio, Inc. Stockholders' Equity:
Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of December 31, 2022 and June 30, 2022, respectively
Common stock - $0.001 par value; 275,000,000 shares authorized at December 31, 2022 and June 30, 2022; 12,368,287 and 8,727,158 shares issued and outstanding as of December 31, 2022 and June 30, 2022, respectively	12,000	9,000
Additional paid-in capital	294,591,000	287,619,000
Accumulated other comprehensive loss	(167,000)	(213,000)
Accumulated deficit	(275,613,000)	(223,930,000)
Total iBio, Inc. Stockholders' Equity	18,823,000	63,485,000
Total Liabilities and Equity	$ 51,800,000	$ 99,406,000